Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vycor Medical (VYCO) Shares Outstanding (Weighted Average) (2016 - 2025)

Vycor Medical has reported Shares Outstanding (Weighted Average) over the past 15 years, most recently at $33.4 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 1.48% to $33.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.4 million through Dec 2025, up 1.48% year-over-year, with the annual reading at $33.4 million for FY2025, 1.48% up from the prior year.
  • Shares Outstanding (Weighted Average) was $33.4 million for Q4 2025 at Vycor Medical, roughly flat from $33.4 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $33.4 million in Q1 2025 and troughed at $27.8 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $32.6 million (2023), against an average of $31.9 million.
  • Year-over-year, Shares Outstanding (Weighted Average) rose 14.87% in 2021 and then changed 0.0% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $29.6 million in 2021, then grew by 7.02% to $31.7 million in 2022, then increased by 2.82% to $32.6 million in 2023, then increased by 0.86% to $32.9 million in 2024, then increased by 1.48% to $33.4 million in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Shares Outstanding (Weighted Average) are $33.4 million (Q4 2025), $33.4 million (Q3 2025), and $33.4 million (Q2 2025).